SR One Capital Management LP acquired a new stake in shares of enGene Holdings Inc. (NASDAQ:ENGN - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 747,750 shares of the company's stock, valued at approximately $1,293,607. enGene makes up 0.0% of SR One Capital Management LP's investment portfolio, making the stock its 15th biggest position. SR One Capital Management LP owned 1.12% of enGene as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently added to or reduced their stakes in the company. Cresset Asset Management LLC acquired a new position in shares of enGene in the 2nd quarter valued at approximately $36,000. Paloma Partners Management Co purchased a new position in enGene during the 2nd quarter valued at about $38,000. Raymond James Financial Inc. increased its stake in enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company's stock valued at $68,000 after purchasing an additional 7,932 shares in the last quarter. Citadel Advisors LLC grew its holdings in enGene by 153.3% during the third quarter. Citadel Advisors LLC now owns 58,370 shares of the company's stock valued at $399,000 after purchasing an additional 35,327 shares during the period. Finally, Millennium Management LLC raised its stake in enGene by 57.3% during the third quarter. Millennium Management LLC now owns 20,502 shares of the company's stock valued at $140,000 after purchasing an additional 7,472 shares in the last quarter. Institutional investors own 64.16% of the company's stock.
Wall Street Analysts Forecast Growth
ENGN has been the subject of several research reports. Leerink Partners lowered enGene from an "outperform" rating to a "market perform" rating and set a $2.00 price objective for the company. in a research note on Friday, May 8th. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $2.00 price target (down from $25.00) on shares of enGene in a report on Friday, May 8th. HC Wainwright cut their price target on enGene from $6.00 to $4.00 and set a "buy" rating for the company in a research note on Tuesday, June 16th. Weiss Ratings reissued a "sell (e+)" rating on shares of enGene in a research note on Wednesday, August 12th. Finally, Citizens Jmp downgraded enGene from an "outperform" rating to a "market perform" rating in a report on Friday, May 8th. Four equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, enGene has a consensus rating of "Hold" and a consensus price target of $11.05.
View Our Latest Stock Analysis on ENGN
enGene Price Performance
Shares of NASDAQ:ENGN traded down $0.07 during mid-day trading on Friday, reaching $1.83. The stock had a trading volume of 266,901 shares, compared to its average volume of 1,018,531. The company has a current ratio of 12.57, a quick ratio of 12.57 and a debt-to-equity ratio of 0.10. The company has a market cap of $122.93 million, a P/E ratio of -0.85 and a beta of -0.28. The business's 50 day moving average price is $1.81 and its 200 day moving average price is $4.50. enGene Holdings Inc. has a 1 year low of $1.40 and a 1 year high of $12.25.
enGene (NASDAQ:ENGN - Get Free Report) last posted its earnings results on Monday, June 15th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.05. During the same quarter in the previous year, the business earned $0.51 EPS. Research analysts expect that enGene Holdings Inc. will post -1.84 EPS for the current fiscal year.
enGene Profile
(
Free Report)
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
See Also
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider enGene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.
While enGene currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
